Felbamate
Felbatol (felbamate) is a small molecule pharmaceutical. Felbamate was first approved as Felbatol on 1993-07-29. It is used to treat complex partial epilepsy, epilepsy, lennox gastaut syndrome, and seizures in the USA.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
Felbatol (generic drugs available since 2011-09-13)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Felbamate
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
FELBATOL | Mylan | N-020189 RX | 1993-07-29 | 3 products, RLD, RS |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
complex partial epilepsy | EFO_1000877 | D017029 | — |
epilepsy | EFO_0000474 | D004827 | G40.9 |
lennox gastaut syndrome | — | D065768 | G40.81 |
seizures | HP_0007359 | D012640 | G40.4 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
19 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Herpes genitalis | D006558 | EFO_0007282 | A60 | — | — | 3 | 3 | — | 6 |
Herpes labialis | D006560 | EFO_1001347 | B00.1 | — | 1 | 1 | 1 | — | 2 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Herpes zoster | D006562 | EFO_0006510 | B02 | — | — | 2 | — | 1 | 3 |
Herpes simplex | D006561 | B00 | — | 1 | 1 | — | — | 2 | |
Chickenpox | D002644 | EFO_0007204 | B01 | — | — | 1 | — | — | 1 |
Meniere disease | D008575 | EFO_0006862 | H81.0 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Multiple sclerosis | D009103 | EFO_0003885 | G35 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | 2 | — | — | — | — | 2 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | FELBAMATE |
INN | felbamate |
Description | Felbamate is the bis(carbamate ester) of 2-phenylpropane-1,3-diol. An anticonvulsant, it is used in the treatment of epilepsy. It has a role as an anticonvulsant and a neuroprotective agent. |
Classification | Small molecule |
Drug class | tranquilizers/antiepileptics (propanediol and pentanediol groups) |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | NC(=O)OCC(COC(N)=O)c1ccccc1 |
Identifiers
PDB | — |
CAS-ID | 25451-15-4 |
RxCUI | 24812 |
ChEMBL ID | CHEMBL1094 |
ChEBI ID | 4995 |
PubChem CID | 3331 |
DrugBank | DB00949 |
UNII ID | X72RBB02N8 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,330 documents
View more details
Safety
Black-box Warning
Black-box warning for: Felbamate, Felbatol
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
977 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more